Connect with us


Bharat Biotech Inks Licensing Deal With Washington University School Of Medicine To Advance COVID-19 Intranasal Vaccine Technology

According to the Chairman of Bharat Biotech, the Phase I trials of the intranasal vaccine for COVID-19 will take place in Saint Louis University’s Vaccine and Treatment Evaluation Unit in USA

Bharat Biotech Inks Licensing Deal With Washington University School of Medicine To Advance COVID-19 Intranasal Vaccine Technology
  • Intranasal vaccine does not need needles and syringes: Dr. Ella
  • Bharat Biotech is also developing COVAXIN which is in Phase 2 trials
  • A nasal vaccine can be useful in controlling COVID-19 spread: Expert

Hyderabad: Vaccine Innovator, Bharat Biotech on Wednesday announced, a licensing agreement with Washington University School of Medicine (WUSM) in St. Louis for a novel chimp-adenovirus, single dose intranasal vaccine for COVID-19. With this, Bharat Biotech owns the right to distribute the vaccine in all markets except the USA, Japan and Europe. The Phase I trials will take place in Saint Louis University’s Vaccine and Treatment Evaluation Unit. While Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India. The company will undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad.

Also Read: Coronavirus Explainer: What Is COVAX Initiative?

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive.”

Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world, Dr Ella stated.

Dr David T Curiel, MD, Ph.D., Director of Biologic Therapeutics Center and Professor of Radiation Oncology at Washington University School of Medicine in St. Louis and Precision Virologics Interim CEO said,

The ability to accomplish effective immunisation with a single nasal dose is a major advantage, offering broader reach and easier administration. An effective nasal dose not only protects against COVID-19, but it also prevents the spread of the disease by offering another kind of immunity that occurs primarily in the cells that line the nose and throat. Most other vaccine candidates currently under development cannot do that.

This vaccine expands Bharat’s portfolio of vaccines that are currently being developed and are in various stages of clinical development including COVAXIN which is currently in Phase II human clinical trials in India.

Also Read: 30 COVID-19 Vaccine Candidates Under Development: Union Minister Harsh Vardhan

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Folk Music For A Swasth India

Folk Music

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पड़े